Show simple item record

dc.contributor.authorCraig, Z.
dc.contributor.authorSwain, J.
dc.contributor.authorSharma, R.
dc.contributor.authorFaluyi, O. O.
dc.contributor.authorWadsley, J.
dc.contributor.authorMorgan, C.
dc.contributor.authorWall, L. R.
dc.contributor.authorChau, I.
dc.contributor.authorReed, N. S.
dc.contributor.authorSarker, D.
dc.contributor.authorMargetts, J.
dc.contributor.authorKrell, D.
dc.contributor.authorCave, J.
dc.contributor.authorSharmila, S.
dc.contributor.authorAnthoney, A.
dc.contributor.authorPatel, A.
dc.contributor.authorLamarca, Angela
dc.contributor.authorHubner, Richard A
dc.contributor.authorValle, Juan W
dc.contributor.authorMcNamara, Mairead G
dc.date.accessioned2023-01-24T10:32:30Z
dc.date.available2023-01-24T10:32:30Z
dc.date.issued2022en
dc.identifier.citationCraig Z, Swain J, Sharma R, Faluyi OO, Wadsley J, Morgan C, et al. Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy. Journal of Clinical Oncology. 2022 Oct;40(28):293-. PubMed PMID: WOS:000891944700291.en
dc.identifier.doi10.1200/JCO.2022.40.28_suppl.293en
dc.identifier.urihttp://hdl.handle.net/10541/625994
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.28_suppl.293en
dc.titleHealth-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLeeds Institute of Clinical Trials Research, University of Leeds, Leedsen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record